Article

A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.

Division of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Tohoku University, Seiryomachi 1-1, Aoba-ku, 980-8574 Sendai, Japan.
Cancer Immunology and Immunotherapy (Impact Factor: 3.94). 07/2004; 53(6):497-509. DOI: 10.1007/s00262-003-0465-9
Source: PubMed

ABSTRACT In the field of cancer immunotherapy research, the targeting of effector cells with specific antibodies is a very promising approach. Recent advances in genetic engineering have made it possible to prepare immunoglobulin fragments consisting of variable domains using bacterial expression systems.
We have produced an anti-epidermal growth-factor receptor (EGFR) x anti-CD3 bispecific diabody (Ex3 diabody) in an Escherichia coli (E. coli) expression system with refolding method. The Ex3 diabody targets lymphokine-activated killer cells with a T-cell phenotype (T-LAK cells) to EGFR positive bile duct carcinoma cells with dramatic enhancement of cytotoxicity in vitro. This specific killing of EGFR-positive cells was completely inhibited by parental mAb IgGs directed to EGFR and the CD3 antigen.
When T-LAK cells were cultured with EGFR-positive tumor cells in the presence of Ex3 diabody, they produced much higher levels of IFN-gamma, GM-CSF, and TNF-alpha than in its absence, this being a possible mechanism underlying specific antitumor activity. The Ex3 diabody showed good stability when tested at 37 degrees C for 48 h, and also markedly inhibited tumor growth of bile duct carcinoma xenografts in severe combined immunodeficient (SCID) mice. When Ex3 diabody (20 microg/mouse) was administrated intravenously, together with T-LAK cells and interleukin-2 (IL-2), complete cure of tumors were observed in three of six mice, and the other three showed marked retardation of tumor growth.
The Ex3 diabody can be considered a highly promising reagent for study of specific targeting immunotherapy against bile duct and other EGFR-positive carcinomas.

Download full-text

Full-text

Available from: Hiroki Hayashi, Apr 05, 2014
0 Followers
 · 
102 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The fragment variable (Fv) represents the smallest part of an antibody containing the entire antigen binding site formed by the variable heavy and light chain domains (VH and VL) (Filpula and McGuire 1999; Chames et al. 2009; Kontermann 2010). Because of the noncovalent interaction between the VH and VL domain, Fv molecules suffer from instability, which can be improved by connecting the two domains with a flexible peptide linker. These single-chain Fv (scFv) fragments can be easily produced in prokaryotic and eukaryotic systems and represent the prototype recombinant antibody format.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bispecific antibodies can serve as mediators to retarget effector mechanisms to disease-associated sites. Studies over the past two decades have revealed the potentials but also the limitations of conventional bispecific antibodies. The development of recombinant antibody formats has opened up the possibility of generating bispecific molecules with improved properties. This review summarizes recent developments in the field of recombinant bispecific antibodies and discusses further requirements for clinical development.
    Acta Pharmacologica Sinica 02/2005; 26(1):1-9. DOI:10.1111/j.1745-7254.2005.00008.x · 2.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Integration of lymphocyte-activating cytokines (e.g., interleukin-12: IL-12) to tumor cells offers promise for cancer immunotherapy, but the preparation of such heterodimeric proteins by refolding is difficult because of subunit instability. We achieved the refolding of Escherichia coli-expressed human IL-12 by a stepwise dialysis method, preventing the formation of insoluble aggregates by adding a redox reagent and an aggregation suppressor. We also constructed a tumor-specific IL-12 protein, each subunit of which was fused with one chain of variable domain fragment (Fv) of anticarcinoembryonic antigen (CEA) antibody T84.66 (aCEA-IL12). Fusion of IL-12 with Fv greatly increased the yield of functional heterodimer. Several assays have indicated that the Fv domain and IL-12 domain of the fused protein had cognate biological activities, and it enhanced the cytotoxicity of T-LAK cells for the cancer cell line.
    Biochemical and Biophysical Research Communications 04/2005; 328(1):98-105. DOI:10.1016/j.bbrc.2004.12.141 · 2.28 Impact Factor